glp·helper
glphelper.com/ozempic/florida/st-petersburg
GLP-1 receptor agonistFDA-approved December 2017Rx · Subcutaneous injection · Once weekly

Ozempic® providers &
prescriptions in St Petersburg, FL

Dr. Fahad Akhtar, M.D.
Medically reviewed by Dr. Fahad Akhtar, M.D.
Physician at g1v.me, an affiliated practice

Ozempic is FDA-approved for type 2 diabetes, not for weight management.[1] The semaglutide approved for chronic weight management is Wegovy in St Petersburg.

Physicians near St Petersburg, FL from the federal NPI registry. Ask each office whether it prescribes Ozempic.[9]

city providers
29
as of today

Same molecule (semaglutide): Wegovy in St Petersburg, Semaglutide in St Petersburg

Other GLP-1 medicines: Tirzepatide in St Petersburg, Mounjaro in St Petersburg, Zepbound in St Petersburg

§ 02Provider directory: Florida
29 of 29 shown

Find an Ozempic provider in St Petersburg.

Every entry comes from the federal NPI registry. Ask each office what it prescribes. We do not accept payment for placement.

Filter →
Type
Provider
City
Insurance / phone
Ozempic by Florida town, physicians per town
§ 03Getting Ozempic in St Petersburg
29 providers · St Petersburg, FL

How to get Ozempic in St Petersburg.

29 GLP-1 prescribers and 7 local resource types are on record for St Petersburg, plus 3 nearby towns in the directory.

Physicians in St Petersburg
29 physicians
29 physicians from the federal NPI registry in St Petersburg, most listed as Family Medicine (14), Internal Medicine (12) and Internal Medicine, Endocrinology, Diabetes & Metabolism (2). A licensed clinician who evaluates you decides whether an FDA-approved GLP-1 fits. Telehealth rules vary by state. The nearest towns on record are Pinellas Park (30 providers), Largo (32 providers) and Clearwater (36 providers).
Around the prescription in St Petersburg
7 listed nearby
3 dietitians, 1 nutritionists, 6 gyms, 6 fitness clubs, 6 trainers, 6 physiotherapists and 6 places to move are on record near St Petersburg.
Medicaid (weight loss)
Diabetes only
As of April 2026, Florida Medicaid covers GLP-1s for diabetes but not for weight loss. Employer and private plans can still cover them; that is a plan-design choice, not a state rule.

Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm Florida’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.

§ 04Medication factsheet
cited · last review 2026.05.19

An injectable medication for adults with type 2 diabetes, and, by indirect effect, for body weight.

Ozempic is the brand name for semaglutide, a once-weekly subcutaneous injection in the GLP-1 receptor agonist class. It mimics a gut hormone that signals satiety to the brain and slows gastric emptying. In the trials on its FDA label, the 1 mg dose lowered HbA1c by 1.4 to 1.9 percentage points and body weight by a mean of 4.7 to 6.0 kg over 30 to 56 weeks. The 2 mg dose lowered body weight by a mean of 6.4 kg over 40 weeks.[2][3]

It is FDA-approved for glycemic control in adults with type 2 diabetes mellitus and for reducing the risk of major cardiovascular events in adults with T2D and established cardiovascular disease. The same molecule, marketed by the same manufacturer as Wegovy, is the FDA-approved formulation for chronic weight management.[1]

For the receptor story in plain English, read how does ozempic work.

Rapid weight loss can change the midface. The mechanism people call ozempic face is in the research notes.

Bar chart of Ozempic dose strengths on the FDA label: 0.25 mg, 0.5 mg, 1 mg, 2 mg
Ozempic comes in 4 strengths: 0.25 mg, 0.5 mg, 1 mg, 2 mg. The chart shows what the label lists. A prescriber sets the dose.[1]
At a glanceNDC 0169-4132
Active ingredient
semaglutide
Drug class
GLP-1 receptor agonist
Manufacturer
Novo Nordisk
FDA approved
December 2017
Approved use
Type 2 diabetes mellitus (adults)
Off-label use
Not FDA-approved for weight management. Wegovy is the semaglutide approved for it
Administration
Subcutaneous injection · Once weekly
Available doses
0.25 mg · 0.5 mg · 1 mg · 2 mg
Half-life
≈ 7 days
Pregnancy
Discontinue ≥ 2 months before planned pregnancy

Community health · CDC

Weight & metabolic health in St. Petersburg

St. Petersburg, Florida has a population of 258,308 people. The adult obesity rate in St. Petersburg is an age-adjusted estimate of 32.5%, 2.9 percentage points above the Florida state rate of 29.6%. Diagnosed diabetes reaches 10.3% of adults in St. Petersburg. Inactivity, meaning no leisure-time physical activity reported in the past month, affects 21.7% of adults in St. Petersburg.

of St. Petersburg adults have obesity
32.5%
diagnosed diabetes
10.3%
no regular physical activity
21.7%

Age-adjusted estimates for St. Petersburg, community figures, not individual risk. CDC PLACES, 2025 release.

Estimate your weight lossGLP-1s and fertility
§ 05Support around Ozempic in St Petersburg
6 fitness clubs

The prescription is one part. Here is the rest, in St Petersburg.

Trials of semaglutide paired the drug with diet counseling and regular activity. Every name below is a real listing near St Petersburg, FL, ordered as the registry lists them, never by who pays us.

Fitness clubs and recreation centers

Fitness clubs and recreation centers run classes and pools, an easier start than a weight room.

Amped Fitness (Tyrone Blvd)
FITNESS
4.2 on Google · 939 reviews
2601 Tyrone Blvd N
Website
Walter Fuller Recreation Center
REC CENTER
4.6 on Google · 689 reviews
7891 26th Ave N
Website
Campbell Park Recreation Center
REC CENTER
4.6 on Google · 627 reviews
601 14th St S
Website
Gladden Park Recreation Center
REC CENTER
4.4 on Google · 532 reviews
3901 30th Ave N
Website
YouFit Gyms St. Petersburg
FITNESS
3.9 on Google · 502 reviews
6157 9th Ave N
Website
St Petersburg Shuffleboard Club
CLUB
4.8 on Google · 500 reviews
559 Mirror Lake Dr N
Website

Registered dietitians

A registered dietitian builds the food plan around your prescription. Call to ask about GLP-1 nutrition plans and insurance.

Kaitlin Dorman, M.S., R.D., L.D.N
RD
Registered dietitian
501 6Th Ave S
Call 727-767-7204NPI 1164886602
Truddie Reif, RDN
RD
Registered dietitian
1700 S Tamiami Trl
Call 941-917-9000NPI 1881576841
Stephanie Tober, RD
RD
Registered dietitian
205 Dr. Mlk St. North
Call 727-824-6900NPI 1861603623
§ 06Clinical evidence
N = 8,416 across SUSTAIN 1 to 7

What the trials actually showed.

We summarize results from the SUSTAIN program, the seven Phase III randomized trials Novo Nordisk submitted to the FDA, and the SUSTAIN-6 cardiovascular outcomes trial. Numbers below are means at the 30-week endpoint, 1 mg weekly dose.

SUSTAIN 1 through 7 compared semaglutide against placebo, sitagliptin, exenatide ER, insulin glargine, and dulaglutide. Semaglutide produced superior HbA1c and body-weight reductions in every active comparator trial.[3]
SUSTAIN endpoint table1 mg / 30 wk
HbA1c reduction
−1.4 to −1.9%
mean, 1 mg dose, 30 to 56 wk[1]
Weight change
−4.7 to −6.0 kg
mean, 1 mg dose, 30 to 56 wk[1]
Major adverse cardiac events
−26%
HR 0.74 vs. placebo[2]
Patients reaching HbA1c <7%
72%
1 mg dose, 30 wk[3]
Effect size varies with baseline characteristics and adherence. Individual response may differ materially.
average Ozempic weight loss →mapped to your starting weight
§ 07Safety & adverse events
from FDA label, sect. 6.1

Most Ozempic side effects are stomach and gut effects.

In Ozempic's diabetes trials at 0.5 mg and 1 mg, the most common side effects were nausea (15.8 to 20.3%), diarrhea (8.5 to 8.8%), and vomiting (5 to 9.2%). Most reports came during dose escalation.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[1]

Boxed warning. Contraindicated in personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Effect
Frequency
Severity
Note
Nausea
15.8 to 20.3%
mild
Most common. Most reports came during dose escalation
Diarrhea
8.5 to 8.8%
mild
More frequent during dose escalation
Vomiting
5 to 9.2%
mild
Reduced by slower titration
Constipation
3.1 to 5%
mild
Abdominal pain
5.7 to 7.3%
moderate
Pancreatitis
<0.3%
serious
Discontinue if confirmed; black-box adjacent
Gallbladder disease
1.5%
serious
Cholelithiasis risk elevated with rapid weight loss
Thyroid C-cell tumors
rodent data
boxed warning
Contraindicated in MTC or MEN-2 history
§ 08Cost & coverage, published, not gated
USD · monthly

What Ozempic costs, by how you pay.

The price you pay depends on your insurance plan, your diagnosis, and how you buy. Manufacturer self-pay programs cost far less than pharmacy retail. Here are the ranges.

Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk self-pay and savings pages.

Self-pay and savings card prices checked . Retail averages from May 2026.

Ozempic monthly cost by how you pay
Pharmacy retail (no insurance)$1,476per monthBrand-name retail average, May 2026[6]
NovoCare self-pay, pen$349 to $499per month0.25, 0.5, and 1 mg $349. 2 mg $499
Commercial insurance (covered)$25 to $250per month copayVaries by PBM; T2D indication usually covered
Weight managementNot approvedOzempic is not FDA-approved for weight management. Wegovy is.
Medicare Part D$0 to $100per monthT2D covered; weight loss not covered by law[5]
Manufacturer savings cardas low as $25per monthCommercial only; eligibility limits apply
Find Ozempic providers in St Petersburg

Physicians from the federal NPI registry. Ask each office whether it prescribes Ozempic.

Ozempic in other states

Physicians from the federal NPI registry in the states we cover. Ask each office whether it prescribes Ozempic.

Related GLP-1 research
§ 09Frequently asked: Ozempic in Florida

The questions people ask before they book.

Answers reviewed by the glp·helper Medical Team. Citations link to primary sources, never marketing copy.

Yes. Ozempic is a prescription-only medicine, marked Rx only on its label. A licensed prescriber (MD, DO, NP, or PA) must evaluate you before issuing a prescription.[1]